India Resurgence Fund is set to acquire the API and CRAMS business of Ind-Swift Laboratories for INR 1,650 crore, according to a joint press release. Ind-Swift is a top ten independent merchant API business in India with a strong market presence and diverse therapeutic presence across multiple regions. The transaction is subject to shareholder and regulatory approvals.